By Helena Smolak
Roche Holding said it will initiate a late-stage trial for its Alzheimer's drug candidate trontinemab later this year after its mid-stage study showed positive results.
The Swiss pharma giant said Thursday during a conference that its experimental treatment showed a reduction of amyloid plaques--protein clumps in the brain that contribute to the disease's progression--in patients with Alzheimer's disease.
In addition, its plasma diagnostics test Elecsys pTau181 demonstrated the ability to determine whether or not someone has amyloid pathology, one of the hallmarks of Alzheimer's disease.
"We are pleased with the progress across our Alzheimer's portfolio as we move ahead with a Phase III trontinemab program and continue to expand our diagnostic solutions," Levi Garraway, Roche's Chief Medical Officer said.
More than 55 million people worldwide are living with dementia, of which around 70% have Alzheimer's. Up to three-quarters of people experiencing symptoms of Alzheimer's remain undiagnosed, according to Roche.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
April 03, 2025 09:30 ET (13:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。